Read expert reviews below or click here for user reviews. Our company has been receiving and recording many benefits related to a wide variety of medical conditions. We only share some of them publicly for regulatory reasons.
Our products are the subject of various ongoing human clinical trials seeking clearance by the U.S. Food and Drug Administration (FDA) and other health authorities around the world for a variety of chronic and acute health conditions.
Please chat or call or email us and share your experience and results. We are excited to inform people about the great benefits of using D’OXYVA®.
“We at Watson Wellness Center in Oakland, CA, are thrilled to announce the launch of a new clinical trial aimed at treating the main underlying medical conditions related to the most severe COVID-19 cases, in partnership with Circularity Healthcare, the makers of D’OXYVA.
This groundbreaking clinical trial will feature the administration of Circularity’s latest patented and patent-pending, noninvasive and painless, ultra-portable, transdermal (over the skin) drug-delivery device D’OXYVA® (deoxyhemoglobin vasodilator). D’OXYVA has consistently demonstrated success over eight years of involvement in dozens of human studies and has received user feedback from thousands of people in dozens of countries when other drugs and treatment options have failed. D’OXYVA directly addresses the issue of low-oxygen blood flow, which is especially important for at-risk COVID-19 patients.”
“Diabetic patients, particularly those with more longstanding and poorly controlled disease, suffer from diminished oxygen-rich blood in their microcirculation. D’OXYVA has shown significant promise for severe cases of diabetic foot ulcers. Its therapeutic effects have circulatory and neurological benefits as well.
Over two dozen studies have demonstrated convincing results at clinics and at home, with no adverse events. D’OXYVA has recorded significant results, delivering major outcomes for well over 90% of users. Studies with D’OXYVA have shown unmatched results in noninvasive wound care – particularly when all other approaches have failed. D’OXYVA provides an adjunct to accelerate comprehensive wound care programs and infection protection as a painless, affordable non-prescription solution available in a clinical setting, or in the comfort and privacy of your own home.”
“Disseminated intravascular coagulation (DIC) is one of the severe complications related to COVID-19. This is a serious disorder in which the proteins that control blood clotting become overactive, which can result in symmetrical peripheral gangrene. The Circularity OTC device is a novel transdermal delivery system that can deliver carbon dioxide directly to body tissues low in oxygen. Further studies are needed, but this device has the potential to prevent symmetrical peripheral gangrene, a limb-threatening complication of COVID-19.”
“The results were pretty astonishing, there was a 6% increase in capillary length (meaning more blood-filled capillaries) and a 14% increase in capillary diameter measuring results with MicroScan after just a few minutes of a single 5-minute (16g CO2) application. The results are more pronounced when considering small vessels (< 20 microns), which include the capillaries. Our early tests suggest D’OXYVA significantly improves blood circulation in the tiniest vessels and more profoundly in people with imbalances in their body than young healthy people.
We are proposing a clinical trial for rheumatoid arthritis patients where we expect significant pain reduction coupled with equally significant circulation improvements in just a month.”
”At European Dermatology London we use the D’OXYVA device after non-surgical aesthetic procedures to help reduce the down-time for patients; and as part of our Medical-grade Pedicures for diabetic patients, who often suffer with impairments in their feet’s microcirculation.”
”In every 30 seconds a diabetic lower limb is lost somewhere in the world. For this reason diabetes and wounds is a dangerous combination; therefore, the management can be difficult. The standard solution of a diabetic wound includes accurate surgical debridement and controlling the diabetic metabolism, as well as eliminating the infection by means of antibiotic solution. In our presented case an insulin-dependent diabetic patient was treated for trimalleolar ankle fracture combined with very serious soft tissue destruction.
After admission to our department the possible solution options were amputation or a long-term combined surgical solution. The patient underwent a very drastic surgical debridement, the necrotised skin was removed. Infection was diagnosed with the identified pathogens being Enterobacter cloacae and ludwigii, Acinetobacter sp., Proteus mirabilis and Escherichia coli. After microbiological consultation an adequate antibiotic solution was introduced. Every two days we repeated the surgical debridement and we applied jet lavage. After ten days there were no further necrotised tissue so we continued with a VAC solution for two weeks. With the assistance of a plastic surgeon we applied Integra® and after a few days a split-thickness skin graft. Patient’s compliance dropped off and needed psychological support. During episodes of confusion he removed the dressings and surprisingly after two weeks fly larvae (Diptera: Sarcophagidae) were found in the skin grafted area.
Then wound improve was accelerated by Bioptron® light solution and D’OXYVA® (deoxyhemoglobin vasodilator) solution was applied twice a day for 25 days. His wound nearly completely healed and closed after 25 days and he could walk with crutches. He was discharged home after three months of solution.
CONCLUSION: Even a serious soft tissue damage can improve after applying adequate solution, but in diabetic patients the decision is difficult. It is important to note that in order to avoid amputation, multidisciplinary approach is mandatory. The patient’s general condition, life expectancy, and compliance basically influence our decisions and during the solution period we have to reassess the results and taking these factors into account, thus we can choose the best solution option.”
”My wife and I definitely noticed a significant increase in vascular aerobic abilities and general vitality. In addition, we exercise aerobically every morning for 50 minutes in our hills and swim 30 minutes. We use this age-old method now available in a powerful advanced small device in the evening before going to bed and it’s a fantastic boost.”
”After four weeks, the patient clinically improved from heart failure symptoms. Objectively, his LVEF was increased from 37.17% to 46.99% and the PaO2 increased from 84.5mmHg to 104.7mmHg.
With no obvious cofounder observed, the deoxyhaemoglobin vasodilator works to improve the LVEF and attenuated the heart failure symptoms. It increased perfusion thus bolstering microcirculation of the heart muscle after the CO2 saturation was increased and induced the vasodilation through Bohr effect.
This great preliminary finding suggested for further studies to be conducted with larger sample size and more objective cardiac function assessment such as through Cardiovascular Magnetic Resonance Imaging (MRI)”
Reduce unwanted doctor visits, recommended and ranked top by experts!